Human Pharmacological Studies with Griseofulvin

Abstract

Twenty-eight patients with tinea capitis, tinea corporis, and/or onychomycosis who were treated with oral griseofulvin (250 mg. four times daily) were studied intensively. The following tests were performed as indicated. Weekly: Complete blood count Routine urine examination Before and after one month medication: Bone marrow examination Blood urea nitrogen Creatinine Uric acid Cephalin flocculation Thymol turbidity Testicular biopsy (two) Electrocardiogram Electroencephalogram Psychological Complete blood counts and bone marrow studies were repeated six weeks after termination of treatment, in each case. In addition, patch tests were performed on 200 individuals, including 28 who had previously received griseofulvin internally. A water-soluble base containing 5% griseofulvin was used. The base, alone, was used as a control. Results All laboratory tests, except the white blood counts, remained essentially unchanged throughout the course of treatment. In 18 (64.3%) patients, a decrease of 10%